Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Distribution, selling, general and administrative expenses

Restructuring and employee severance

Amortization and other acquisition-related costs

Impairments and (gain)/loss on disposal of assets, net

Litigation (recoveries)/charges, net

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Cardinal Health

Cordis develops and manufactures medical devices for diagnostics and interventional procedures to treat patients suffering from coronary and peripheral vascular diseases.On October 4, 2015, Cardinal Health announced that it has completed the acquisition of Johnson & Johnson's Cordis business for $1.944 billion.

Cordis

Cardinal Health, Inc. is a healthcare services and products company, which engages in the provision of customized solutions for hospitals, healthcare systems, pharmacies, ambulatory surgery centers, clinical laboratories, and physician offices. It also provides medical products and pharmaceuticals and cost-effective solutions that enhance supply chain efficiency. The firm operates through the Pharmaceutical and Medical segments. The Pharmaceutical segment distributes branded and generic pharmaceutical, specialty pharmaceutical and over-the-counter healthcare and consumer products. The Medical segment manufactures, sources and distributes Cardinal Health branded medical, surgical, and laboratory products. The company was founded by Robert D. Walter in 1979 and is headquartered in Dublin, OH.

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Earnings data Q1 2025

Earnings data Q2 2025

Cardinal Health reports strong Q3 results, focuses on Pharma growth

Cardinal Health's Q3 results demonstrated strong performance in the Pharma segment, while the Medical segment faced challenges. The company raised its guidance for the year and emphasized the importance of Red Oak Sourcing in maintaining market dynamics. Looking ahead, the company is focused on executing its medical improvement plan and maximizing shareholder value.

Cardinal Health reports stable Q2 growth, eyes Pharma segment

Cardinal Health's Q2 2023 performance showcased stability and growth in the Pharma segment, with a return to profitability in the Medical segment.
The company's strategic focus on executing key priorities and driving shareholder value creation is evident in its financial results.
Challenges such as international freight costs and supply chain headwinds are being addressed, while opportunities in COVID therapies, pricing strategy, and growth investments are being pursued.
Overall, Cardinal Health's revised outlook and strong performance in key segments position it for continued growth and financial success.

Cardinal Health reports robust Q3 earnings, eyes biosimilars for growth

Cardinal Health delivered strong financial performance in Q3 2023, driven by robust growth in the Pharma segment.
While facing challenges in the Medical segment, the company remains focused on mitigating inflation and maximizing shareholder value.
With a positive outlook on future growth opportunities, Cardinal Health aims to address cost pressures and drive profitability.

Cardinal Health achieves record results, raises guidance for fiscal '24

Cardinal Health's strong performance in Q4 and fiscal year 2023, coupled with strategic initiatives and guidance raise, position the company for continued growth and success.
Challenges such as inflation mitigation and cost pressures are being addressed, while opportunities in organic growth and strategic investments pave the way for future profitability.
The company's focus on advancing Pharma, executing the Medical Improvement Plan, and maximizing shareholder value creation underscores its commitment to sustained growth and value creation.

Cardinal Health reports strong Q1 earnings, raises guidance for FY24

Cardinal Health's Q1 2024 earnings call showcased robust performance, with profit growth in both Pharma and Medical segments. The company raised EPS guidance, demonstrated strong cash flow generation, and emphasized customer service and shareholder value creation. Challenges include managing margins, nonoperating items, and commodity price impacts, while opportunities lie in healthcare sector growth, innovation, and market dynamics.

Cardinal Health reports robust Q2 earnings, raises EPS guidance

Cardinal Health's Q2 performance reflects strong revenue growth, improved cash flow, and raised EPS guidance, supported by strategic acquisitions and growth initiatives.
While facing challenges from nonrecurring adjustments and SG&A growth, the company remains focused on core businesses and driving future growth opportunities.
With a positive outlook on market-driven growth, cost management, and strategic priorities, Cardinal Health aims to sustain its momentum and deliver value to shareholders.

Cardinal Health reports robust Q3 earnings, eyes growth opportunities ahead

Cardinal Health's Q3 performance reflects strong financial results and strategic progress across key segments, with raised guidance for fiscal '24 and '25.
The company faces challenges such as managing customer transitions and inflationary impacts but is well-positioned to capitalize on growth opportunities.
By focusing on cost optimization, strategic partnerships, and customer-centric solutions, Cardinal Health aims to drive sustained growth and profitability.
Investments in technology, brand growth, and operational efficiency underscore Cardinal Health's commitment to delivering value to shareholders and customers.

Cardinal Health excels in fiscal '24, raises guidance for '25

Cardinal Health's strong performance in fiscal year '24, highlighted by record financial results and strategic progress, positions the company for continued success.
Despite challenges such as market dynamics and customer transitions, the company's raised guidance for fiscal year '25 underscores confidence in future growth.
By capitalizing on strengths like revenue growth in key segments and making strategic investments, Cardinal Health is poised to navigate challenges and seize opportunities for sustained growth.

Cardinal Health reports strong Q1 performance and raises fiscal guidance

Cardinal Health's Q1 performance showed strength in Pharma and Specialty Solutions despite revenue decrease.
Challenges in GMPD segment and nuclear supply disruptions are being addressed for minimal impact.
Opportunities lie in continued cost reductions, growth normalization, and operational improvements.
Overall, Cardinal Health is well-positioned to navigate challenges and capitalize on growth opportunities.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Here's Why Cardinal Health (CAH) is a Strong Momentum Stock

In the closing of the recent trading day, Cardinal Health (CAH) stood at $111.92, denoting a -0.52% change from the preceding trading day.

Cardinal Health (CAH) Stock Dips While Market Gains: Key Facts

Cardinal Health and T2 Biosystems announce an agreement selecting the former to sell direct-from-blood diagnostics for the rapid detection of sepsis-causing pathogens.

CAH Stock May Gain Following the Distribution Deal With T2 Biosystems

CAH gains from a solid pharmaceutical segment and a diversified product portfolio. However, regulatory setbacks are a concern.

Reasons to Retain Cardinal Health Stock in Your Portfolio Now

Why Cardinal Health (CAH) is a Top Value Stock for the Long-Term

CAH is set to acquire Oncology Network for $1.115 billion, expanding its oncology offerings while supporting community-based cancer care across 10 states.

Cardinal Health Stock Likely to Gain From the Acquisition of ION

DUBLIN, Ohio , Sept. 24, 2024 /PRNewswire/ -- Cardinal Health (NYSE: CAH) plans to release first-quarter financial results for its fiscal year 2025 on November 1, prior to the opening of trading on the New York Stock Exchange.

Cardinal Health to Announce First-Quarter Results for Fiscal Year 2025 on November 1

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Is Cardinal Health (CAH) Stock Undervalued Right Now?

Cardinal Health on Friday agreed to acquire Integrated Oncology Network, an independent community oncology network, for $1.12 billion in cash.

Cardinal Health to acquire Integrated Oncology Network for $1.12 billion

Transaction demonstrates Cardinal Health's continued strategic investment in specialty and oncology, underscores commitment to independent community healthcare providers  Accelerates the development of Navista oncology practice alliance , adding more than 100 providers at more than 50 community-based sites delivering broad-reaching oncology and urology care across 10 states DUBLIN, Ohio , Sept. 20, 2024 /PRNewswire/ -- Cardinal Health (NYSE: CAH) announced today that it has entered into a definitive agreement to acquire Integrated Oncology Network (ION), a physician-led independent community oncology network, for $1.115B in cash.

Cardinal Health to acquire Integrated Oncology Network, a physician-led independent community oncology network

Cardinal Health (CAH) reachead $110.76 at the closing of the latest trading day, reflecting a -0.58% change compared to its last close.

Cardinal Health (CAH) Stock Falls Amid Market Uptick: What Investors Need to Know

Dublin, Sept. 19, 2024 (GLOBE NEWSWIRE) -- The "Bioactive Dressings Market by Product (Collagen, Alginate, Chitosan, Skin Substitute), Property (Antimicrobial, Non-Antimicrobial), Application (Chronic Wounds (Diabetic Foot, Pressure Ulcers), Acute Wounds (Surgical, Burns))- Global Forecast to 2029" report has been added to ResearchAndMarkets.com's offering. The global bioactive dressings market is projected to reach USD 5.8 billion by 2029 from USD 3.5 billion in 2024, at a CAGR of 10.5% during the forecast period.

Bioactive Dressings - Comprehensive Global and Regional Market Forecast to 2029 - Featuring Strategical Analysis of 3M, Smith+Nephew, Cardinal Health, Braun, Molnlycke Health Care, Convatec & More

Cardinal Health and Telix announce an agreement selecting the former as a commercial radiopharmaceutical distributor to supply finished unit doses of Telix's Zircaix.

CAH Stock May Gain Following the Distribution Agreement With Telix

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

Why Cardinal Health (CAH) is a Top Momentum Stock for the Long-Term

MELBOURNE, Australia, Sept. 17, 2024 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces that it has selected Cardinal Health, Inc. (NYSE: CAH, Cardinal Health) as a commercial radiopharmaceutical distributor to supply finished unit doses of its PET1 agent, Zircaix®2 (TLX250-CDx) for the imaging of kidney cancer in the United States (U.S.), subject to regulatory approval.

Telix Announces Cardinal Health as U.S. Commercial Distributor for Zircaix®

In the latest trading session, Cardinal Health (CAH) closed at $113.28, marking a +0.1% move from the previous day.

Here's Why Cardinal Health (CAH) Gained But Lagged the Market Today

Realty Income Corp

Sysco

Dividend investing has proved to be a reliable source of income for investors while allowing for long-term generational wealth accumulation.

Not All Dividend Aristocrats Are Created Alike. Here Are the 3 You Should Buy

Cardinal Health, Inc. (NYSE:CAH ) Baird's 2024 Global Healthcare Conference September 10, 2024 9:05 AM ET Company Participants Matt Sims - VP, IR Jason Hollar - CEO Aaron Alt - CFO Conference Call Participants Eric Coldwell - Baird Eric Coldwell Good morning, everyone. My name is Eric Coldwell.

Cardinal Health, Inc. (CAH) Baird's 2024 Global Healthcare Conference (Transcript)

WASHINGTON and DUBLIN, Ohio , Sept. 10, 2024 /PRNewswire/ -- In observance of today's World Suicide Prevention Day, Children's Hospital Association (CHA), Cardinal Health (NYSE: CAH), and Zero Suicide Institute (ZSI) celebrate early success of the Preventing Youth Suicide Collaborative, a collaborative funded by the Cardinal Health Foundation, led by CHA, and informed by ZSI's prevention expertise.

Children's Hospital Association and Cardinal Health commemorate World Suicide Prevention Day with continued focus on youth mental health

The latest trading day saw Cardinal Health (CAH) settling at $112.80, representing a +0.92% change from its previous close.

Cardinal Health (CAH) Advances But Underperforms Market: Key Facts

Cardinal Health, Inc. (NYSE:CAH ) Morgan Stanley 22nd Annual Global Healthcare Conference September 5, 2024 8:30 AM ET Company Participants Matt Sims - VP, IR Aaron Alt - CFO Conference Call Participants Erin Wright – Morgan Stanley Erin Wright Hi, good morning, everyone. My name is Erin Wright.

Cardinal Health (CAH) Morgan Stanley 22nd Annual Global Healthcare Conference Transcript

Cardinal Health announces the opening of its new distribution center in Greenville to support its at-Home Solutions business.

Greenville Center to Boost CAH Stock's at-Home Solution Business

Altria

Taiwan Semiconductor Manufacturing

Everybody loves dividends, as they provide a passive income stream, limit drawdowns in other positions, and provide more than one way to profit from an investment.

3 Consistent Dividend Growers to Buy for Passive Income: TSM, MO, CAH

'Warehouse of the Future' to expand nationwide distribution network in support of home healthcare growth DUBLIN, Ohio , Aug. 28, 2024 /PRNewswire/ -- Cardinal Health (NYSE: CAH) officially announced today the recent opening of a new distribution center in Greenville, South Carolina dedicated solely to its at-Home Solutions business, expected to add roughly 200 jobs to the region over time. Cardinal Health at-Home Solutions is a leading provider of home healthcare medical supplies, helping more than five million customers nationwide manage their medical supply needs, including those who have chronic or critical medical conditions.

Cardinal Health celebrates Greenville, South Carolina, distribution center opening

Cardinal Health stock remains a buy due to strong pharmaceutical business growth and increased shareholder returns, despite short-term OptumRx and inflation challenges. Q4 and FY24 earnings exceeded expectations with revenue up 12% and gross margin up 5%, driven by pharmaceutical and medical products. DCF analysis supports a $128 price target, 17% upside, with Wall Street's average at $116; industry tailwinds bolster valuation.

News for Cardinal Health Stock (CAH)